Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 4/20 | 0.62 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.62 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.62 |
| ▸ | ALPI | P09923 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | XIAP | P98170 | 1/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.47 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.46 |
| ▸ | LAP3 | P28838 | 3/20 | 0.46 |
| ▸ | CPA1 | P15085 | 2/20 | 0.46 |
| ▸ | CPA3 | P15088 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2890750 | 1.00 | SLC1A3 (0.62) | SLC1A3SLC1A2SLC1A1ALPIPKM | |
| SCHEMBL27348648 | 0.90 | SLC1A3 (0.69) | SLC1A3SLC1A2SLC1A1ALPIPKM | |
| Diethylamine SCHEMBL29024453 | 0.89 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1ALPIPKM | |
| Diethylamine SCHEMBL29024452 | 0.89 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1ALPIPKM | |
| SCHEMBL14420246 | 0.84 | SLC1A3 (0.61) | SLC1A3SLC1A2SLC1A1ALPIPKM | |
| SCHEMBL14420344 | 0.84 | SLC1A3 (0.61) | SLC1A3SLC1A2SLC1A1ALPIPKM | |
| SCHEMBL4367490 | 0.84 | SLC1A3 (0.61) | SLC1A3SLC1A2SLC1A1ALPIPKM | |
| SCHEMBL1101111 | 0.84 | SLC1A3 (0.61) | SLC1A3SLC1A2SLC1A1ALPIPKM | |
| SCHEMBL27644705 | 0.84 | SLC1A3 (0.61) | SLC1A3SLC1A2SLC1A1ALPIPKM | |
| SCHEMBL27665297 | 0.81 | SLC1A3 (0.57) | SLC1A3SLC1A2SLC1A1ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807678-B2 | Peptidomimetics of biologically active metallopeptides | PALATIN TECHNOLOGIES, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7718802-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7655658-B2 | Use of in the treatment of melanocortin receptor-associated disorders such as in treatment of anorexia, as a weight gain aid, for treatment of obesity | PALATIN TECHNOLOGIES, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| WO-2009144432-A1 | MC4-R AGONISTS FOR THE TREATMENT OF OBESITY | PALATIN TECHNOLOGIES, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
| US-7550602-B1 | Small molecule compositions for sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7456184-B2 | Melanocortin receptor-specific compounds | PALATIN TECHNOLOGIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| EP-1622618-A4 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES INC (US) | 2008-08-27 | — | — | EP | disclosed |
| US-7326707-B2 | Bicyclic melanocortin-specific compounds | PALATIN TECHNOLOGIES INCORPORATED (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1425029-A4 | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES | PALATIN TECHNOLOGIES INC (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1622618-A1 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | Palatin Technologies, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2005102340-A1 | PIPERAZINE MELANOCORTIN-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005079574-A1 | BICYCLIC MELANOCORIN-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050176728-A1 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | PALATIN TECHNOLOGIES, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2004098602-A1 | MELANOCORTIN RECEPTOR-SPECIFIC COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2004-11-18 | — | — | WO | disclosed |
| EP-1425029-A1 | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES | Palatin Technologies, Inc. (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003013571-A1 | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176728-A1 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders | MC3R, MC4R, MC1R | SLC1A3 919/4885SLC1A2 614/4885SLC1A1 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.